Title: High adherence to oral anticancer treatment in patients with metastatic renal cancer
Authors: De Coster, Sandra
Lacour, V
De Gieter, K
Deckeyser, I
Hendrickx, T
Haenen, I
Kestens, E
Ligneel, C
Verhavert, E
Nagels, K
Ninane, C
Doquire, AS
Van Thienen, AM
Wolter, Pascal
Foulon, Veerle #
Issue Date: 2012
Conference: ESCP edition:41 location:Barcelona date:28-30 October 2012
Abstract: Abstract: Background & Objectives
Patient adherence to oral therapy is an emerging issue in cancer treatment. Therefore, the aim of the IPSOC-study
(Investigating Patient Satisfaction with Oral anti-Cancer treatment) is to investigate the prevalence and severity of nonadherence
to oral anticancer drugs (OAD) in metastatic renal cell cancer (mRCC) and to identify factors predictive of nonadherence.
Settings & Method
Prospective observational multicenter trial performed at 11 Belgian hospitals. All patients with mRCC starting OADs are
eligible for the study. Patients are contacted by phone at baseline and at 1, 3, 6 and 12 months. At each contact, patients
are asked to complete questionnaires investigating 1) medication adherence (MMAS), 2) patient satisfaction with
treatment (CTSQ) and with treatment education (PS-CaTE), 3) extent of information desire (EID) and 4) quality of life
(FACT-G). Adherence is measured with MEMS® (Aardex).
Main outcome measures
Adherence to OAD
Between 02/2011 and 05/2012, 80 patients with a median age of 65 years have participated in the IPSOC-study. With a
median follow-up of 150 days (range 3 - 465), 87% of patients claimed to be fully adherent (based on MMAS and CTSQ
data). Ten patients indicated to have missed at least one dose, for which the most important reasons were forgetting
(38% of cases) and side effects (31%). Based on MEMS® data, mean adherence, defined as the percentage of days with
at least the prescribed number of dosage taken, was 97.95%. Interestingly, the prescribed regimen was changed or
interrupted by the treating oncologist in 36% of cases.
Median EID and FACT-G scores were significantly higher at baseline compared to 1 month of treatment (p<0,05). The
mean score for the CTSQ subdomain ‘satisfaction with treatment’ was higher at month 3 compared to month 1 (p<0,05)
while the mean score for ‘feelings about side effects’ decreased significantly between month 1 and 3.
The IPSOC study, the first to examine adherence to OAD among mRCC patients, shows that mRCC patients are almost
fully adherent to treatment recommendations. This seems to be in contrast to adherence data for other, long-lasting, anticancer
Publication status: published
KU Leuven publication type: IMa
Appears in Collections:Research Centre for Pharmaceutical Care and Pharmaco-economics (-)
Laboratory of Experimental Oncology
# (joint) last author

Files in This Item:
File Description Status SizeFormat
ESCP12-1678-v1 ISPOC.pdf Published 78KbAdobe PDFView/Open


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science